OXALIPLATIN

Post-LOE

oxaliplatin

Accord Biopharma

ANDAINTRAVENOUSINJECTABLE

Approved

Sep 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

OXALIPLATIN (oxaliplatin) by Accord Biopharma is ligand. Approved for colorectal cancer. First approved in 2017.

Drug data last refreshed 19h ago

Mechanism of Action

ligand. Several transient reactive species are formed, including monoaquo and diaquo DACH platinum, which covalently bind with macromolecules. Both inter-and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent…

Pharmacologic Class:

Platinum-based Drug

Indications (1)

colorectal cancer

Clinical Trials (20)

NCT07490301Phase 2/3Not Yet Recruiting

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Started Jun 2026

900 enrolled

Metastatic Pancreatic Ductal AdenocarcinomaPDAC

NCT07281768Phase 2Not Yet Recruiting

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Started May 2026

66 enrolled

Colorectal Cancer

NCT07483684Phase 3Not Yet Recruiting

A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

Started Mar 2026

142 enrolled

HER2 IHC3+ Advanced Colorectal Cancer

NCT07384377Phase 3Not Yet Recruiting

JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan

Started Feb 2026

123 enrolled

HER2-positive Colorectal Cancer

NCT06624085Phase 1Recruiting

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Started Apr 2025

50 enrolled

Lymphoma

Worked on OXALIPLATIN at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.